Publications - February 2021
Preprint and peer-reviewed publications from RECOVER’s studies
SARS-CoV-2 B.1.1.7 and B.1.351 variants emerged respectively in United Kingdom and South Africa and spread in many countries. Here, we isolated infectious B.1.1.7 and B.1.351 strains and examined their sensitivity to anti-SARS-CoV-2 antibodies present in sera and nasal swabs, in comparison with a D614G reference virus. tocilizumab and sarilumab, improved outcome, including survival.
Facing B.1.1.7 variant, social distancing was strengthened in France in January 2021. Using a 2-strain mathematical model calibrated on genomic surveillance, we estimated that social distancing allowed hospitalizations to plateau, by decreasing transmission of the historical strain while B.1.1.7 continued to grow. Variant dominance is expected by the end of February-early March in France, with large geographical heterogeneity. Without strengthened social distancing, a rapid surge of hospitalizations is expected in the next weeks.